

## References

- Akoglu, H. (2018). User's guide to correlation coefficients. *Turkish Journal of Emergency Medicine*, 18(3), 91–93. <https://doi.org/10.1016/j.tjem.2018.08.001>
- Amengual, J. E., Johannet, P., Lombardo, M., Zullo, K., Hoehn, D., Bhagat, G., Scotto, L., Jirau-Serrano, X., Radeski, D., Heinen, J., Jiang, H., Cremers, S., Zhang, Y., Jones, S., & O'Connor, O. A. (2015). Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. *Clinical Cancer Research*, 21(20), 4663–4675. <https://doi.org/10.1158/1078-0432.CCR-14-3068>
- Anders, C. K., Johnson, R., Litton, J., Phillips, M., & Bleyer, A. (2009). Breast Cancer Before Age 40 Years. *Seminars in Oncology*, 36(3), 237–249. <https://doi.org/10.1053/j.seminoncol.2009.03.001>
- Antoni, D., Burckel, H., Josset, E., & Noel, G. (2015). Three-Dimensional Cell Culture: A Breakthrough in Vivo. *International Journal of Molecular Sciences*, 16(12), 5517–5527. <https://doi.org/10.3390/ijms16035517>
- Aykul, S., & Martinez-Hackert, E. (2016). Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis. *Analytical Biochemistry*, 508, 97–103. <https://doi.org/10.1016/j.ab.2016.06.025>
- Ben Youssef, B. (2016). Cellular Automata-Based Modeling of Three-Dimensional Multicellular Tissue Growth. In *Emerging Trends in Applications and Infrastructures for Computational Biology, Bioinformatics, and Systems Biology* (pp. 287–303). Elsevier. <https://doi.org/10.1016/B978-0-12-804203-8.00019-5>
- Berens, E. B., Holy, J. M., Riegel, A. T., & Wellstein, A. (2015). A Cancer Cell Spheroid Assay to Assess Invasion in a 3D Setting. *Journal of Visualized Experiments*, 105, 53409.

<https://doi.org/10.3791/53409>

Białkowska, K., Komorowski, P., Bryszewska, M., & Miłowska, K. (2020). Spheroids as a Type of Three-Dimensional Cell Cultures—Examples of Methods of Preparation and the Most Important Application. *International Journal of Molecular Sciences*, *21*(17), 6225.

<https://doi.org/10.3390/ijms21176225>

Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016). Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. *Nature Reviews Clinical Oncology*, *13*(11), 674–690. <https://doi.org/10.1038/nrclinonc.2016.66>

Brandvold, K. R., Steffey, M. E., Fox, C. C., & Soellner, M. B. (2012). Development of a Highly Selective c-Src Kinase Inhibitor. *ACS Chemical Biology*, *7*(8), 1393–1398.

<https://doi.org/10.1021/cb300172e>

Chalukur-Ramireddy, N. K. R., & Pakala, S. B. (2018). Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer. *Bioscience Reports*, *38*(1), BSR20171357.

<https://doi.org/10.1042/BSR20171357>

Charpentier, M., & Martin, S. (2013). Interplay of Stem Cell Characteristics, EMT, and Microtentacles in Circulating Breast Tumor Cells. *Cancers*, *5*(4), 1545–1565.

<https://doi.org/10.3390/cancers5041545>

Chavez, K. J., Garimella, S. V., & Lipkowitz, S. (2011). Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer. *Breast Disease*, *32*(1–2), 35–48. <https://doi.org/10.3233/BD-2010-0307>

<https://doi.org/10.3233/BD-2010-0307>

Chen, J., Elfiky, A., Han, M., Chen, C., & Saif, M. W. (2014). The Role of Src in Colon Cancer and Its Therapeutic Implications. *Clinical Colorectal Cancer*, *13*(1), 5–13.

<https://doi.org/10.1016/j.clcc.2013.10.003>

Chua, K.-N., Sim, W.-J., Racine, V., Lee, S.-Y., Goh, B. C., & Thiery, J. P. (2012a). A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma. *PLoS One*, *7*(3), e33183. <https://doi.org/10.1371/journal.pone.0033183>

- Chua, K.-N., Sim, W.-J., Racine, V., Lee, S.-Y., Goh, B. C., & Thiery, J. P. (2012b). A Cell-Based Small Molecule Screening Method for Identifying Inhibitors of Epithelial-Mesenchymal Transition in Carcinoma. *PLoS ONE*, *7*(3), e33183. <https://doi.org/10.1371/journal.pone.0033183>
- Costa, E. C., Moreira, A. F., de Melo-Diogo, D., Gaspar, V. M., Carvalho, M. P., & Correia, I. J. (2016). 3D tumor spheroids: An overview on the tools and techniques used for their analysis. *Biotechnology Advances*, *34*(8), 1427–1441. <https://doi.org/10.1016/j.biotechadv.2016.11.002>
- Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature*, *378*(6559), 785–789. <https://doi.org/10.1038/378785a0>
- Cushing, M. C., & Anseth, K. S. (2007). Hydrogel Cell Cultures. *Science*, *316*(5828), 1133–1134. <https://doi.org/10.1126/science.1140171>
- De Niz, C., Rahman, R., Zhao, X., & Pal, R. (2016). Algorithms for Drug Sensitivity Prediction. *Algorithms*, *9*(4), 77. <https://doi.org/10.3390/a9040077>
- Dent, R., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2009). Pattern of metastatic spread in triple-negative breast cancer. *Breast Cancer Research and Treatment*, *115*(2), 423–428. <https://doi.org/10.1007/s10549-008-0086-2>
- Dhaliwal, A. (2012). Three Dimensional Cell Culture: A Review. *Materials and Methods*, *2*. <https://doi.org/10.13070/mm.en.2.162>
- Dokmanovic, M., Clarke, C., & Marks, P. A. (2007). Histone Deacetylase Inhibitors: Overview and Perspectives. *Molecular Cancer Research*, *5*(10), 981–989. <https://doi.org/10.1158/1541-7786.MCR-07-0324>
- Duda, P., Akula, S. M., Abrams, S. L., Steelman, L. S., Martelli, A. M., Cocco, L., Ratti, S., Candido, S., Libra, M., Montalto, G., Cervello, M., Gizak, A., Rakus, D., & McCubrey, J. A. (2020). Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. *Cells*, *9*(5), 1110. <https://doi.org/10.3390/cells9051110>

- Dujon, A. M., Capp, J.-P., Brown, J. S., Pujol, P., Gatenby, R. A., Ujvari, B., Alix-Panabières, C., & Thomas, F. (2021). Is There One Key Step in the Metastatic Cascade? *Cancers*, *13*(15), 3693. <https://doi.org/10.3390/cancers13153693>
- Eckstein, F., Wunderer, C., Boehm, H., Kuhn, V., Priemel, M., Link, T. M., & Lochmüller, E.-M. (2003). Reproducibility and Side Differences of Mechanical Tests for Determining the Structural Strength of the Proximal Femur. *Journal of Bone and Mineral Research*, *19*(3), 379–385. <https://doi.org/10.1359/JBMR.0301247>
- Figueiredo Filho, D. B., Silva Júnior, J. A., & Rocha, E. C. (2011). What is R2 all about? *Leviathan (São Paulo)*, *3*, 60. <https://doi.org/10.11606/issn.2237-4485.lev.2011.132282>
- Fisusi, F. A., & Akala, E. O. (2019). Drug Combinations in Breast Cancer Therapy. *Pharmaceutical Nanotechnology*, *7*(1), 3–23. <https://doi.org/10.2174/2211738507666190122111224>
- Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). Triple-Negative Breast Cancer. *New England Journal of Medicine*, *363*(20), 1938–1948. <https://doi.org/10.1056/NEJMra1001389>
- Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009). Triple-negative breast cancer—Current status and future directions. *Annals of Oncology*, *20*(12), 1913–1927. <https://doi.org/10.1093/annonc/mdp492>
- Gonçalves, H., Guerra, M. R., Duarte Cintra, J. R., Fayer, V. A., Brum, I. V., & Bustamante Teixeira, M. T. (2018). Survival Study of Triple-Negative and Non–Triple-Negative Breast Cancer in a Brazilian Cohort. *Clinical Medicine Insights: Oncology*, *12*, 117955491879056. <https://doi.org/10.1177/1179554918790563>
- Götschel, F., Kern, C., Lang, S., Sparna, T., Markmann, C., Schwager, J., McNelly, S., von Weizsäcker, F., Laufer, S., Hecht, A., & Merfort, I. (2008). Inhibition of GSK3 differentially modulates NF-κB, CREB, AP-1 and β-catenin signaling in hepatocytes, but fails to promote TNF-α-induced apoptosis. *Experimental Cell Research*, *314*(6), 1351–1366. <https://doi.org/10.1016/j.yexcr.2007.12.015>
- Gray, M. J., Zhang, J., Ellis, L. M., Semenza, G. L., Evans, D. B., Watowich, S. S., & Gallick, G. E. (2005).

- HIF-1 $\alpha$ , STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. *Oncogene*, 24(19), 3110–3120. <https://doi.org/10.1038/sj.onc.1208513>
- Green, T. P., Fennell, M., Whittaker, R., Curwen, J., Jacobs, V., Allen, J., Logie, A., Hargreaves, J., Hickinson, D. M., Wilkinson, R. W., Elvin, P., Boyer, B., Carragher, N., Plé, P. A., Bermingham, A., Holdgate, G. A., Ward, W. H. J., Hennequin, L. F., Davies, B. R., & Costello, G. F. (2009). Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. *Molecular Oncology*, 3(3), 248–261. <https://doi.org/10.1016/j.molonc.2009.01.002>
- Greenburg, G., & Hay, E. D. (1982). Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. *Journal of Cell Biology*, 95(1), 333–339. <https://doi.org/10.1083/jcb.95.1.333>
- Gucalp, A., Sparano, J. A., Caravelli, J., Santamauro, J., Patil, S., Abbruzzi, A., Pellegrino, C., Bromberg, J., Dang, C., Theodoulou, M., Massague, J., Norton, L., Hudis, C., & Traina, T. A. (2011). Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. *Clinical Breast Cancer*, 11(5), 306–311. <https://doi.org/10.1016/j.clbc.2011.03.021>
- Gunti, S., Hoke, A. T. K., Vu, K. P., & London, N. R. (2021). Organoid and Spheroid Tumor Models: Techniques and Applications. *Cancers*, 13(4), 874. <https://doi.org/10.3390/cancers13040874>
- Habanjar, O., Diab-Assaf, M., Caldefie-Chezet, F., & Delort, L. (2021). 3D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages. *International Journal of Molecular Sciences*, 22(22), 12200. <https://doi.org/10.3390/ijms222212200>
- Haisler, W. L., Timm, D. M., Gage, J. A., Tseng, H., Killian, T. C., & Souza, G. R. (2013). Three-dimensional cell culturing by magnetic levitation. *Nature Protocols*, 8(10), 1940–1949. <https://doi.org/10.1038/nprot.2013.125>
- Hamilton, D. F., Ghert, M., & Simpson, A. H. R. W. (2015). Interpreting regression models in clinical outcome studies. *Bone & Joint Research*, 4(9), 152–153.

<https://doi.org/10.1302/2046-3758.49.2000571>

Harrell, F. E. (2015). Multivariable Modeling Strategies. In F. E. Harrell , *Regression Modeling Strategies* (pp. 63–102). Springer International Publishing.

[https://doi.org/10.1007/978-3-319-19425-7\\_4](https://doi.org/10.1007/978-3-319-19425-7_4)

Hay, E. D. (1995). An Overview of Epithelio-Mesenchymal Transformation. *Cells Tissues Organs*, *154*(1), 8–20. <https://doi.org/10.1159/000147748>

Hennequin, L. F., Allen, J., Costello, G. F., Fennell, M., Green, T. P., Jacobs, V., Morgentin, R., Olivier, A., & Ple, P. A. (2005). The discovery of AZD0530: A novel, oral, highly selective and dual-specific inhibitor of the Src and Abl family kinases. *Cancer Research*, *65*(9\_Supplement), 595–595.

Hosmer, D. W., Lemeshow, S., & Sturdivant, R. X. (2013). *Applied Logistic Regression* (1st ed.). Wiley.

<https://doi.org/10.1002/9781118548387>

Hsu, P.-C., Yang, C.-T., Jablons, D. M., & You, L. (2020). The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC). *Cancers*, *12*(6), 1361.

<https://doi.org/10.3390/cancers12061361>

Huber, M. A., Kraut, N., & Beug, H. (2005). Molecular requirements for epithelial–mesenchymal transition during tumor progression. *Current Opinion in Cell Biology*, *17*(5), 548–558.

<https://doi.org/10.1016/j.ceb.2005.08.001>

Imamura, Y., Mukohara, T., Shimono, Y., Funakoshi, Y., Chayahara, N., Toyoda, M., Kiyota, N., Takao, S., Kono, S., Nakatsura, T., & Minami, H. (2015). Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. *Oncology Reports*, *33*(4), 1837–1843.

<https://doi.org/10.3892/or.2015.3767>

Jaynes, J., Ding, X., Xu, H., Wong, W. K., & Ho, C.-M. (2013). Application of fractional factorial designs to study drug combinations. *Statistics in Medicine*, *32*(2), 307–318.

<https://doi.org/10.1002/sim.5526>

Jaynes, J., Wong, W., & Xu, H. (2016). Using blocked fractional factorial designs to construct discrete choice experiments for healthcare studies. *Statistics in Medicine*, *35*(15), 2543–2560.

<https://doi.org/10.1002/sim.6882>

- Jia, X., Li, Y., Sharma, A., Li, Y., Xie, G., Wang, G., Jiang, J., Cheng, Y., & Ding, X. (2017). Application of sequential factorial design and orthogonal array composite design (OACD) to study combination of 5 prostate cancer drugs. *Computational Biology and Chemistry*, *67*, 234–243. <https://doi.org/10.1016/j.compbiolchem.2017.01.010>
- Kapałczyńska, M., Kolenda, T., Przybyła, W., Zajączkowska, M., Teresiak, A., Filas, V., Ibbs, M., Bliźniak, R., Łuczewski, Ł., & Lamperska, K. (2016). 2D and 3D cell cultures – a comparison of different types of cancer cell cultures. *Archives of Medical Science*. <https://doi.org/10.5114/aoms.2016.63743>
- Kim, H.-Y. (2019). Statistical notes for clinical researchers: Simple linear regression 3 – residual analysis. *Restorative Dentistry & Endodontics*, *44*(1), e11. <https://doi.org/10.5395/rde.2019.44.e11>
- Langhans, S. A. (2018). Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning. *Frontiers in Pharmacology*, *9*, 6. <https://doi.org/10.3389/fphar.2018.00006>
- Law, A. M. K., Rodriguez De La Fuente, L., Grundy, T. J., Fang, G., Valdes-Mora, F., & Gallego-Ortega, D. (2021). Advancements in 3D Cell Culture Systems for Personalizing Anti-Cancer Therapies. *Frontiers in Oncology*, *11*, 782766. <https://doi.org/10.3389/fonc.2021.782766>
- Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietsenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *Journal of Clinical Investigation*, *121*(7), 2750–2767. <https://doi.org/10.1172/JCI45014>
- Li, H., Zhang, Z., Zhou, Z., Ding, X., & Zhou, G. (2016). Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo. *Anti-Cancer Drugs*, *27*(7), 600–608. <https://doi.org/10.1097/CAD.0000000000000365>
- Li, S., Liu, X., Chen, X., Zhang, L., & Wang, X. (2015). Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling. *Tumor Biology*, *36*(12), 9661–9665.

<https://doi.org/10.1007/s13277-015-3747-x>

- Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., Cristofanilli, M., Hortobagyi, G. N., & Pusztai, L. (2008). Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. *Journal of Clinical Oncology*, *26*(8), 1275–1281.  
<https://doi.org/10.1200/JCO.2007.14.4147>
- Lin, N. U., Claus, E., Sohl, J., Razzak, A. R., Arnaout, A., & Winer, E. P. (2008). Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. *Cancer*, *113*(10), 2638–2645.  
<https://doi.org/10.1002/cncr.23930>
- Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G.-H., Tan, Y., Zhang, Z., Lin, X., & He, X. (2002). Control of  $\beta$ -Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism. *Cell*, *108*(6), 837–847.  
[https://doi.org/10.1016/S0092-8674\(02\)00685-2](https://doi.org/10.1016/S0092-8674(02)00685-2)
- Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. *Nature Reviews Drug Discovery*, *8*(8), 627–644. <https://doi.org/10.1038/nrd2926>
- Liu, T., Brouha, B., & Grossman, D. (2004). Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. *Oncogene*, *23*(1), 39–48.  
<https://doi.org/10.1038/sj.onc.1206978>
- Lv, D., Hu, Z., Lu, L., Lu, H., & Xu, X. (2017). Three-dimensional cell culture: A powerful tool in tumor research and drug discovery (Review). *Oncology Letters*.  
<https://doi.org/10.3892/ol.2017.7134>
- Malorni, L., Shetty, P. B., De Angelis, C., Hilsenbeck, S., Rimawi, M. F., Elledge, R., Osborne, C. K., De Placido, S., & Arpino, G. (2012). Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. *Breast Cancer Research and Treatment*, *136*(3), 795–804. <https://doi.org/10.1007/s10549-012-2315-y>
- Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000). Histone Deacetylase Inhibitors: Inducers of



- Differentiation or Apoptosis of Transformed Cells. *JNCI Journal of the National Cancer Institute*, 92(15), 1210–1216. <https://doi.org/10.1093/jnci/92.15.1210>
- Martin, M., Rehani, K., Jope, R. S., & Michalek, S. M. (2005). Toll-like receptor–mediated cytokine production is differentially regulated by glycogen synthase kinase 3. *Nature Immunology*, 6(8), 777–784. <https://doi.org/10.1038/ni1221>
- Martin, P., Owen, S. P., & Leighl, N. B. (2013). Gefitinib: Re-emerging from the shadows. *Lung Cancer Management*, 2(5), 423–437. <https://doi.org/10.2217/lmt.13.42>
- Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., Symmans, W. F., & Ueno, N. T. (2013). Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. *Clinical Cancer Research*, 19(19), 5533–5540. <https://doi.org/10.1158/1078-0432.CCR-13-0799>
- Medunjanin, S., Schleithoff, L., Fiegehenn, C., Weinert, S., Zuschratter, W., & Braun-Dullaeus, R. C. (2016). GSK-3 $\beta$  controls NF-kappaB activity via IKK $\gamma$ /NEMO. *Scientific Reports*, 6(1), 38553. <https://doi.org/10.1038/srep38553>
- Meijer, L., Skaltsounis, A.-L., Magiatis, P., Polychronopoulos, P., Knockaert, M., Leost, M., Ryan, X. P., Vonica, C. A., Brivanlou, A., Dajani, R., Crovace, C., Tarricone, C., Musacchio, A., Roe, S. M., Pearl, L., & Greengard, P. (2003). GSK-3-Selective Inhibitors Derived from Tyrian Purple Indirubins. *Chemistry & Biology*, 10(12), 1255–1266. <https://doi.org/10.1016/j.chembiol.2003.11.010>
- Mittal, V. (2018). Epithelial Mesenchymal Transition in Tumor Metastasis. *Annual Review of Pathology: Mechanisms of Disease*, 13(1), 395–412. <https://doi.org/10.1146/annurev-pathol-020117-043854>
- NCCN Guidelines for Patients: Metastatic Breast Cancer*. (2023).
- Nguyen, D. X., Bos, P. D., & Massagué, J. (2009). Metastasis: From dissemination to organ-specific colonization. *Nature Reviews Cancer*, 9(4), 274–284. <https://doi.org/10.1038/nrc2622>

- Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., Heller, R., Ellis, L. M., Karras, J., Bromberg, J., Pardoll, D., Jove, R., & Yu, H. (2002). Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. *Oncogene*, *21*(13), 2000–2008. <https://doi.org/10.1038/sj.onc.1205260>
- Nowak-Sliwinska, P., Weiss, A., Ding, X., Dyson, P. J., van den Bergh, H., Griffioen, A. W., & Ho, C.-M. (2016). Optimization of drug combinations using Feedback System Control. *Nature Protocols*, *11*(2), 302–315. <https://doi.org/10.1038/nprot.2016.017>
- Ognjenovic, V., Brtko, V., Stojanov, J., Brtko, E., & Berkovic, I. (2022). The Cuts Selection Method Based on Histogram Segmentation and Impact on Discretization Algorithms. *Entropy*, *24*(5), 675. <https://doi.org/10.3390/e24050675>
- Oswald, A. J., Symeonides, S. N., Wheatley, D., Chan, S., Brunt, A. M., McAdam, K., Schmid, P., Waters, S., Poole, C., Twelves, C., Perren, T., Bartlett, J., Piper, T., Chisholm, E. M., Welsh, M., Hill, R., Hopcroft, L. E. M., Barrett-Lee, P., & Cameron, D. A. (2023). Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): A randomised phase II study. *Breast Cancer Research and Treatment*, *199*(1), 35–46. <https://doi.org/10.1007/s10549-023-06873-8>
- Perou, C. M. (2011). Molecular Stratification of Triple-Negative Breast Cancers. *The Oncologist*, *16*(S1), 61–70. <https://doi.org/10.1634/theoncologist.2011-S1-61>
- Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, Ø., Pergamenschikov, A., Williams, C., Zhu, S. X., Lønning, P. E., Børresen-Dale, A.-L., Brown, P. O., & Botstein, D. (2000). Molecular portraits of human breast tumours. *Nature*, *406*(6797), 747–752. <https://doi.org/10.1038/35021093>
- Petrelli, F., Coinu, A., Borgonovo, K., Cabiddu, M., Ghilardi, M., Lonati, V., & Barni, S. (2014). The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: A systematic review and meta-analysis. *Breast Cancer Research and Treatment*, *144*(2), 223–232. <https://doi.org/10.1007/s10549-014-2876-z>

- Prat, A., Pineda, E., Adamo, B., Galván, P., Fernández, A., Gaba, L., Díez, M., Viladot, M., Arance, A., & Muñoz, M. (2015). Clinical implications of the intrinsic molecular subtypes of breast cancer. *The Breast*, *24*, S26–S35. <https://doi.org/10.1016/j.breast.2015.07.008>
- Rädler, P. D., Wehde, B. L., Triplett, A. A., Shrestha, H., Shepherd, J. H., Pfefferle, A. D., Rui, H., Cardiff, R. D., Perou, C. M., & Wagner, K.-U. (2021). Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells. *Nature Communications*, *12*(1), 3742. <https://doi.org/10.1038/s41467-021-23957-5>
- Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2008). Basal-like breast cancer: A critical review. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, *26*(15), 2568–2581. <https://doi.org/10.1200/JCO.2007.13.1748>
- Rampioni Vinciguerra, G. L., Dall'Acqua, A., Segatto, I., Mattevi, M. C., Russo, F., Favero, A., Cirombella, R., Mungo, G., Viotto, D., Karimbayli, J., Pesce, M., Vecchione, A., Belletti, B., & Baldassarre, G. (2021). P27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer. *Cell Death & Disease*, *12*(10), 951. <https://doi.org/10.1038/s41419-021-04241-2>
- Richards, R., Schwartz, H. R., Honeywell, M. E., Stewart, M. S., Cruz-Gordillo, P., Joyce, A. J., Landry, B. D., & Lee, M. J. (2020). Drug antagonism and single-agent dominance result from differences in death kinetics. *Nature Chemical Biology*, *16*(7), 791–800. <https://doi.org/10.1038/s41589-020-0510-4>
- Ryu, N.-E., Lee, S.-H., & Park, H. (2019). Spheroid Culture System Methods and Applications for Mesenchymal Stem Cells. *Cells*, *8*(12), 1620. <https://doi.org/10.3390/cells8121620>
- Santo, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., Cirstea, D., Rodig, S., Eda, H., Scullen, T., Canavese, M., Bradner, J., Anderson, K. C., Jones, S. S., & Raje, N. (2012). Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. *Blood*, *119*(11), 2579–2589.

<https://doi.org/10.1182/blood-2011-10-387365>

Schneider, A., Hommel, G., & Blettner, M. (2010). Linear Regression Analysis. *Deutsches Ärzteblatt International*. <https://doi.org/10.3238/arztebl.2010.0776>

Schober, P., & Vetter, T. R. (2021). Linear Regression in Medical Research. *Anesthesia & Analgesia*, *132*(1), 108–109. <https://doi.org/10.1213/ANE.0000000000005206>

Schott, A. F., & Hayes, D. F. (2012). Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer. *Journal of Clinical Oncology*, *30*(15), 1747–1749.

<https://doi.org/10.1200/JCO.2011.41.3161>

Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., Fatima, A., Gelman, R. S., Ryan, P. D., Tung, N. M., De Nicolo, A., Ganesan, S., Miron, A., Colin, C., Sgroi, D. C., ... Garber, J. E. (2010). Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. *Journal of Clinical Oncology*, *28*(7), 1145–1153.

<https://doi.org/10.1200/JCO.2009.22.4725>

Stambolic, V., & Woodgett, J. R. (1994). Mitogen inactivation of glycogen synthase kinase-3  $\beta$  in intact cells via serine 9 phosphorylation. *Biochemical Journal*, *303*(3), 701–704.

<https://doi.org/10.1042/bj3030701>

Stiborova, M., Eckschlager, T., Poljakova, J., Hrabeta, J., Adam, V., Kizek, R., & Frei, E. (2012). The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment. *Current Medicinal Chemistry*, *19*(25),

4218–4238. <https://doi.org/10.2174/092986712802884286>

Sundaramurthi, H., Giricz, Z., & Kennedy, B. N. (2022). Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma. *International Journal of Molecular Sciences*, *23*(16), 9378. <https://doi.org/10.3390/ijms23169378>

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, *71*(3), 209–249.

<https://doi.org/10.3322/caac.21660>

- Sutherland, C., Leighton, I. A., & Cohen, P. (1993). Inactivation of glycogen synthase kinase-3  $\beta$  by phosphorylation: New kinase connections in insulin and growth-factor signalling. *Biochemical Journal*, 296(1), 15–19. <https://doi.org/10.1042/bj2960015>
- Tate, C. R., Rhodes, L. V., Segar, H. C., Driver, J. L., Pounder, F. N., Burow, M. E., & Collins-Burow, B. M. (2012). Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. *Breast Cancer Research*, 14(3), R79. <https://doi.org/10.1186/bcr3192>
- Thiery, J. P. (2003). Epithelial–mesenchymal transitions in development and pathologies. *Current Opinion in Cell Biology*, 15(6), 740–746. <https://doi.org/10.1016/j.ceb.2003.10.006>
- Thiery, J. P., & Sleeman, J. P. (2006). Complex networks orchestrate epithelial–mesenchymal transitions. *Nature Reviews Molecular Cell Biology*, 7(2), 131–142. <https://doi.org/10.1038/nrm1835>
- Treter, J., Bonatto, F., Krug, C., Soares, G. V., Baumvol, I. J. R., & Macedo, A. J. (2014). Washing-resistant surfactant coated surface is able to inhibit pathogenic bacteria adhesion. *Applied Surface Science*, 303, 147–154. <https://doi.org/10.1016/j.apsusc.2014.02.123>
- Tseng, L. M., Hsu, N. C., Chen, S. C., Lu, Y. S., Lin, C. H., Chang, D. Y., Li, H., Lin, Y. C., Chang, H. K., Chao, T. C., Ouyang, F., & Hou, M. F. (2013). Distant metastasis in triple-negative breast cancer. *Neoplasma*, 60(03), 290–294. [https://doi.org/10.4149/neo\\_2013\\_038](https://doi.org/10.4149/neo_2013_038)
- Vetter, T. R., & Schober, P. (2018). Regression: The Apple Does Not Fall Far From the Tree. *Anesthesia & Analgesia*, 127(1), 277–283. <https://doi.org/10.1213/ANE.0000000000003424>
- Vijay, G. V., Zhao, N., Den Hollander, P., Toneff, M. J., Joseph, R., Pietila, M., Taube, J. H., Sarkar, T. R., Ramirez-Pena, E., Werden, S. J., Shariati, M., Gao, R., Sobieski, M., Stephan, C. C., Sphyris, N., Miura, N., Davies, P., Chang, J. T., Soundararajan, R., ... Mani, S. A. (2019). GSK3 $\beta$  regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer. *Breast Cancer Research*, 21(1), 37. <https://doi.org/10.1186/s13058-019-1125-0>
- Wang, D.-Y., Jiang, Z., Ben-David, Y., Woodgett, J. R., & Zacksenhaus, E. (2019). Molecular stratification

- within triple-negative breast cancer subtypes. *Scientific Reports*, 9(1), 19107.  
<https://doi.org/10.1038/s41598-019-55710-w>
- Webster, M.-T., Rozycka, M., Sara, E., Davis, E., Smalley, M., Young, N., Dale, T. C., & Wooster, R. (2000). Sequence variants of the axin gene in breast, colon, and other cancers: An analysis of mutations that interfere with GSK3 binding. *Genes, Chromosomes and Cancer*, 28(4), 443–453. [https://doi.org/10.1002/1098-2264\(200008\)28:4<443::AID-GCC10>3.0.CO;2-D](https://doi.org/10.1002/1098-2264(200008)28:4<443::AID-GCC10>3.0.CO;2-D)
- Wilkinson, L. (1979). Tests of significance in stepwise regression. *Psychological Bulletin*, 86(1), 168–174. <https://doi.org/10.1037/0033-2909.86.1.168>
- Wu, K., Kuo, C., & Tu, T. (2021). A Highly Reproducible Micro U-Well Array Plate Facilitating High-Throughput Tumor Spheroid Culture and Drug Assessment. *Global Challenges*, 5(2), 2000056. <https://doi.org/10.1002/gch2.202000056>
- Xu, H., Jaynes, J., & Ding, X. (2013). Combining two-level and three-level orthogonal arrays for factor screening and response surface exploration. *Statistica Sinica*.  
<https://doi.org/10.5705/ss.2012.210>
- Zhang, L., Fang, C., Xu, X., Li, A., Cai, Q., & Long, X. (2015). Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis. *BioMed Research International*, 2015, 1–12. <https://doi.org/10.1155/2015/357485>